.png)
British toddler Opal Sandy has had her hearing restored thanks to a first-of-its-kind gene therapy. Eighteen-month-old Opal received the treatment as part of the CHORD study (sponsored by biotechnology company, Regeneron), which offers the therapy – DB-OTO – to children born with OTOF linked hearing loss. The Guardian reported last month that Opal’s parents “couldn’t really believe it,” when their daughter was able to hear for the first time after receiving the treatment.
Establishing robust policy frameworks to support precision medicine involves creating an ecosystem that fosters innovation, ensures safety and efficacy, and promotes equitable access. This includes addressing challenges and opportunities related to privacy, data protection, insurance, and genetic discrimination. Here, we outline the key strategies and components for setting up such programs, focusing on regulatory frameworks, data infrastructure, funding, ethical considerations, and collaborative ecosystems.
In the recent webinar hosted by Jess Burrows, Product Designer at Sano Genetics, and Marisa Ngbemeneh, Product Manager at Sano Genetics, we took a deep dive into the importance of patient-centric design in healthcare. The conversation highlighted how prioritising the patient experience can significantly improve clinical trials and research initiatives.
Precision medicine is transforming healthcare by tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. Our latest whitepaper, "From policy to practise: Integrating precision medicine into healthcare systems," highlights how effective policies can make this a reality.
In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had a fascinating conversation with Michelle Werner, CEO of Alltrna and CEO/Partner at Flagship Pioneering. Michelle and her team are pushing the boundaries of tRNA therapies, aiming to provide scalable treatment options for people with rare and ultra-rare diseases.
To fully harness the potential of genomics for early detection and prevention in at-risk populations, a comprehensive and strategic approach is crucial. Below, we outline key strategies to leverage genetic discoveries for driving early detection and prevention, particularly in vulnerable groups. The ultimate goal? To improve health outcomes and alleviate the burden on healthcare systems.
Genomics has come a long way since the first human genome was sequenced in 2003. Today, sequencing a genome is not only faster but also significantly more affordable, thanks to advancements from industry leaders like Illumina and Oxford Nanopore. This progress has opened new avenues for research and precision medicine, particularly in identifying and supporting at-risk populations.
In this webinar, "Light The Way: Lessons learned from a genetic testing, education, and support platform," Paul Wicks shares an in-depth update on the “Light the Way” programme. He explores the methodologies used, the challenges addressed, and the progress made to-date in supporting individuals with genetic forms of motor neurone disease (MND), also known as amyotrophic lateral sclerosis (ALS).
In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had the pleasure of speaking with Almut Heinken, a junior professor at the INSERM Institute of Nutrition, Genetics, Environment, and Risk Exposure at Université de Lorraine. Almut’s fascinating research sits at the intersection of the microbiome, human genetics, drug discovery, and pharmacogenomics.
In this webinar, "Alpha-1 Antitrypsin Deficiency: Engagement, screening, and retention," Sano Senior Project Manager, Hayley Holt, shares a case study on our work with an industry-leading sponsor to deliver genetically-qualified volunteers for a precision medicine clinical trial focused on Alpha-1 Antitrypsin Deficiency (AATD). The webinar explores the methodologies used and describes the success of the project.